News | June 03, 2021
Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Aurobindo has one of the most enduring generics ecosystems among peers
This marks Glenmark's first synthetic decapeptide injectable approval
R&D Centre will be housed in Baddi and will cater to all business divisions in addition to expansion plans for all its verticals including APls, Formulations and Medical Devices
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Subscribe To Our Newsletter & Stay Updated
